Aldeyra Therapeutics, Inc.
General ticker "ALDX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $253.8M (TTM average)
Aldeyra Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -28.0%.
Estimated limits based on current volatility of 2.1%: low 1.46$, high 1.53$
Factors to consider:
- Total employees count: 9 (-10.0%) as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: FDA approval delays, Commercialization delays, Manufacturing disruptions, Labor/talent shortage/retention, Capital shortage
- Current price 57.6% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.51$, 8.43$]
- 2026-12-31 to 2027-12-31 estimated range: [3.11$, 7.58$]
Financial Metrics affecting the ALDX estimates:
- Positive: with PPE of -9.2 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -10.60 <= 0.28
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 15.17 > -0.64
- Positive: 42.26 < Shareholder equity ratio, % of 61.41 <= 63.63
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of 0 <= 0
Short-term ALDX quotes
Long-term ALDX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $42.79MM | $60.12MM | $35.27MM |
| Operating Income | $-42.79MM | $-60.12MM | $-35.27MM |
| Non-Operating Income | $5.25MM | $4.27MM | $1.42MM |
| Interest Expense | $2.07MM | $1.93MM | $1.91MM |
| R&D Expense | $29.46MM | $48.22MM | $25.66MM |
| Income(Loss) | $-37.54MM | $-55.85MM | $-33.85MM |
| Net Income(Loss)* | $-37.54MM | $-55.85MM | $-33.85MM |
| Stockholders Equity | $119.80MM | $71.00MM | $44.25MM |
| Assets | $148.33MM | $104.61MM | $72.06MM |
| Operating Cash Flow | $-30.33MM | $-43.21MM | $-33.35MM |
| Investing Cash Flow | $30.00MM | $-44.92MM | $47.74MM |
| Financing Cash Flow | $-1.27MM | $-0.17MM | $1.12MM |
| Earnings Per Share** | $-0.64 | $-0.94 | $-0.56 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.